搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
FierceBiotech
26 天
Gura's weekly amylin obesity asset well tolerated, tied to weight loss in phase 1 trial
a combination of long-acting amylin analog cagrilintide and GLP-1 agonist semaglutide. The Big Pharma is currently testing the obesity treatment out in phase 3 trials, with a readout expected ...
Bloomberg on MSN
1 个月
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
(Bloomberg) -- Novo Nordisk A/S’s appetite-blocking shot semaglutide, sold under the ... The key to the new combination is a ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Murder suspect detained
Not guilty in subway death
Record 15-yr, $765M deal
Red-flag warnings in CA
On birthright citizenship
Cardiovascular disease risk
China deploys 90 ships
Syria's chemical weapons hit
Quakes hit Alaska islands
Counselor to the president
Bans cancer causing solvents
Accused in civil lawsuit
Exits as RNC co-chair
2024 word of the year
China opens investigation
Camerota to exit CNN
Andy Kim takes office early
Kanlaon volcano erupts
Wins Hero World Challenge
Baseball’s HOF inductees
Women drop lawsuit
Earth drier since 1990
Golden Globes nominations
Deputy secretary of state
Seeks to pause US ban
X removes image generator
Ink distribution deal
Swift’s Eras Tour ends
Tops box office again
Set to take witness stand
Travel ban on SK president
MX flight diversion attempt
反馈